Chimeric antigen receptor T (CAR-T) cell therapy has shown promising results for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The immune response induced by murine singlechain variable fragment (scFv) of the CAR may limit CAR-T cell persistence and thus increases the risk of leukemia relapse. In this study, we developed a novel humanized scFv from the murine FMC63 antibody. A total of 18 R/R ALL patients with or without prior murine CD19 CAR-T therapy were treated with humanized CD19-targeted CAR-T cells (hCART19s). After lymphodepletion chemotherapy with cyclophosphamide and fludarabine, the patients received a single dose (1 3 10 6 /kg) of autologous hCART19s infusion. Among the 14 patients without previous CAR-T therapy, 13 (92.9%) achieved complete remission (CR) or CR with incomplete count recovery (CRi) on day 30, whereas 1 of the 3 patients who failed a second murine CAR-T infusion achieved CR after hCART19s infusion. At day 180, the overall and leukemia-free survival rates were 65.8% and 71.4%, respectively. The cumulative incidence of relapse was 22.6%, and the nonrelapse mortality rate was 7.1%. During treatment, 13 patients developed grade 1-2 cytokine release syndrome (CRS), 4 patients developed grade 3-5 CRS, and 1 patient experienced reversible neurotoxicity.
| B AC KGR OUND
The adoptive transfer of chimeric antigen receptor T (CAR-T) cell represents a highly promising strategy to fight against multiple cancers.
1 -5 Although CARs are generated for a variety of cell surface molecules, such as HER2, mesothelin and carbonic anhydrase IX (CAIX), [6] [7] [8] the most impressive therapeutic effect is observed in the use of CD19-targeted CAR-T cells in treating B cell malignancies. [9] [10] [11] [12] [13] [14] The available results show that 70%-90% of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients who receive CD19 CAR-T therapy achieve complete remission (CR) 15 and that the regression of leukemia 
| hCART19s generation
The humanized scFv sequence specific for CD19 was derived from Clone FMC63 as previously described. 18 The humanized scFv sequence was inserted in tandem with the human CD8 transmembrane, CD8 hinge, 4-1BB costimulatory domain, CD3f intracellular regions and T2A-EGFRt sequence. 16, 19 The hCART19s were acquired through the transfection of lentivirus carrying a CAR sequence of humanized anti-CD19 scFv into peripheral CD3 1 T cells. Detailed information is provided in Supporting Information methods.
| Quality control of hCART19s prior to infusion
To evaluate the therapeutic potential of hCART19s, we conducted preclinical assessments of the effect of hCART19s in vitro and on xenograft animal models (see Supporting Information methods). All mouse studies were performed in accordance with the guidelines for the Welfare Of Animals In Experimental Neoplasia by the United Kingdom
Coordinating Committee on Cancer Research (UKCCCR). In addition, bacteria, fungi, chlamydia, mycoplasma, and endotoxin were detected twice to prevent potential contamination before hCART19s infusion.
| hCART19s infusion
Peripheral blood mononuclear cells (PBMCs) were obtained from patients by leukapheresis for hCART19s preparation on day 211, and the first day of hCART19sinfusion was set on day 0. 
| Clinical response assessment
To assess the efficacy of hCART19s, peripheral blood (PB) and bone marrow samples from each patient were obtained every 1-2 months before and after infusion. Cytokine release syndrome (CRS) grading and other toxicities were assessed as previously described. 20 
| Statistics
Comparisons of continuous variables and risk factors that may influence variations in severe CRS development were performed using the Mann-Whitney U test for two groups. The Kaplan-Meier approach was performed to estimate time-to-event analyzes. All statistical analyzes were performed using SPSS, and P values less than .05 were considered significant.
| RE S U L TS

| Preclinical evaluation of hCART19s
Based on mouse anti-human CD19 antibody (FMC63), we obtained the humanized anti-human CD19 antibody (Clone H3L2) with high affinity (Supporting Information Figure S1A ). In vitro experiments demonstrated that hCART19s carrying the CAR sequence of humanized anti-CD19 scFv could efficiently eliminate CD19-expressing cells (Supporting Information Figure S1B ,C). The secretion of cytokines by hCART19s, IL-2 and IFN-g, was dramatically increased following engagement with the target cells (Supporting Information Figure S1D , E). Moreover, in a human leukemia xenograft animal model, we found that hCART19s were capable of eradicating Nalm6 cells in NOD/SCID mice (Supporting Information Figure S1F ). These data showed that hCART19s targeting human CD19 antigen were functional both in vitro and in vivo.
| Patient characteristics
From May 2016 to August 2017, 18 R/R CD19 1 B-ALL patients, aged from 3 to 57 years old, with a median age of 14 years old, were enrolled into the present trial ( Table 1 A total of 4 patients had central nervous system leukemia (CNSL), and 1 had testicular leukemia (TL).
| Clinical response after hCART19s infusion
On day 30 after infusion, the treatment response was evaluated in 17/ 18 patients (Table 1) 
| In vivo expansion and persistence of hCART19s
The amplification and survival of peripheral hCART19s were monitored by FACS and QPCR analyzes ( Figure 1 ). In 18 patients, the amplification of hCART19s peaked on days 7-14 after infusion, followed by a decrease in the cell number and copies of hCART19s with a prolonged follow-up period. FACS analysis showed that hCART19s was not detectable on day 30 in 15 patients, with only 2 patients presenting few hCART19s on day 60 ( Figure 1A ,B). In the PB of patients with 
| Prognosis
The median follow-up time was 244 days (ranging from 105 to 624 days) in these 17 patients, except patient No. 5. In the 14 patients receiving hCART19s infusion who achieved CR or CRi, there were 7 patients maintaining CR with MRD negative (Table 1) Figure S2B ). In the enrolled patients, at 180 days, the overall survival (OS) rate was 65.8% (95% CI 39.1%-83.0%) (Figure 2A) , and the leukemia-free survival (LFS) rate was 71.4% (95% CI 40.6%-88.2%) ( Figure 2B ). The cumulative incidence of relapse (CIR) was 22.6% (Figure 2C) , and the nonrelapse mortality (NRM) rate was 7.1% ( Figure   2D ).
| Toxicities after hCART19s infusion
In our study, 17 of the 18 patients (94.4%) experienced CRS. Among these patients, 13 had grade 1-2 CRS, and 4 had grade 3-5 CRS (Figure 3A) . CRS primarily occurred within a median of 6 days after infusion (range 1 to 9 days) and lasted for a median of 7 days (range 2 to 14 days). Fever with higher temperature was observed in all 17
patients and lasted longer period for patients with grade 3-5 CRS The characteristics of patients and clinical responses after hCART19s infusion CAR copies/lg DNA in CSF and 54678 CAR copies/lg DNA in PB.
After mannitol treatment, neurotoxicity was ameliorated on day 19. patients with R/R B-ALL were recruited into this clinical trial.
On day 30 after hCART19s infusion, a high CR rate was observed in enrolled patients. In patients who had not previously received CD19
CAR-T therapy, 13 patients (92.9%) obtained CR or CRi, among whom 11 patients achieved CR with MRD negative, and the CR rate was comparable or even superior to those in previous studies using murine scFvderived CAR-T cells. [9] [10] [11] 23 A total of 3 patients with CNSL and/or TL also obtained CR, suggesting that hCART19s, similar to murine-derived CD19 CAR-T cells, can migrate into the tumor site and exert an antitumor effect in bone marrow, central nervous system and the testis. These data showed that humanized CD19 CAR-T cells could be used to effectively treat pediatric or adult R/R B-ALL and would benefit patients who did not respond to multiple infusions of murine CAR-T cells.
CRS is the most common acute toxicity of CAR-T cells, which is considered as a systemic inflammatory response resulting from CAR-T cell activation and proliferation. [24] [25] [26] [27] In our study, 94.4% patients experienced the signs and symptoms of CRS, with 22.2% of the patients showing severe CRS, which is consistent with previous studies. Neurotoxicity is another side effect associated with CAR-T cell therapy and is often accompanied by the occurrence of CRS. Once CRS was relieved, neurotoxicity was also ameliorated. [9] [10] [11] However, neurotoxicity does not always occur with the presence of systemic CRS, and the mechanism remains unclear. In our study, reversible neurotoxicity was only observed in 1 patient (5.6%) after hCART19s infusion, and the incidence rate of neurotoxicity was lower as compared to reported data by other studies. 16, 23, [28] [29] [30] In addition, elevated amplification of CAR-T cells and increased cytokines were detected in CSF, which is in accordance with other reports. 9, 10, 23, 31 However, whether increased cytokines in CSF are associated with neurotoxicity need to be illustrated in prospective studies and with more samples.
Relapse remains a major problem for CD19 CAR-T cell therapy, despite a promising high CR rate. In line with other studies, loss of CAR-T cells is one of the causes for relapse. We found 4 patients relapse between 100-250 days after hCART19s infusion because of limited persistence and loss of hCART19s in vivo. Although humanized modification may decrease the immunogenicity, prolong CAR-T cell persistence and improve therapeutic efficiency, the limitation is still occurred in the present study. Nevertheless, allo-HSCT is a potential approach to reduce leukemia relapse in patients who achieved CR after CD19 CAR-T therapy. Some studies showed that CAR-T cells might effectively serve as a "bridge to transplant" that potentially could improve the outcome of allo-HSCT for these patients. 10, 30, 32 However, a previous study in MSKCC showed that the 6-month OS did not significantly differ between patients who underwent allo-HSCT after achieving CR with CD19 CAR-T cells and those who did not. 33 In the present study, 2 patients received allo-HSCT after achieving CR by hCART19s therapy, among whom 1 patient is currently in CR with MRD-negative and the other patient died from GVHD and severe infection. With a limited sample size and follow-up period, these results showed that allo-HSCT can reduce the leukemia relapse for patients who achieved CR after hCART19s therapy; however, transplantation-associated complications might affect the disease-free survival. More importantly, for the first time, we reported 2 patients receiving auto-HSCT maintained CR with MRD negative after achieving CR through hCART19s therapy. These results showed that auto-HSCT may be another strategy to reduce leukemia relapse for patients with R/R B-ALL who cannot receive allo-HSCT after achieving CR with CAR-T therapy.
| CON CL U S I ONS
Taking the results together, this study demonstrated that hCART19s
have high therapeutic efficacy in children and adults with R/R B-ALL.
More importantly, hCART19s was confirmed to exert anti-leukemic activities in patients who did not respond to multiple murine CAR-T infusions. In patients with R/R B-ALL, an in-depth study of the persistence of hCART19s and the anti-CAR immune response will be critical to improve the sustained remission rate.
